Bd reports third quarter fiscal 2022 financial results

Revenue from continuing operations of $4.6 billion increased 0.7% as reported and 3.8% on currency-neutral basis revenue from continuing operations driven by base revenue growth of 6.0% as reported, 9.3% currency-neutral worldwide covid-only testing revenues of $76 million declined from $300 million in the prior year gaap diluted eps from continuing operations of $1.28; adjusted diluted eps from continuing operations of $2.66 company raises full year revenue and eps guidance franklin lakes, n.j. , aug. 4, 2022 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced results for its third quarter of fiscal year 2022, which ended june 30, 2022.
BDX Ratings Summary
BDX Quant Ranking